Johnson & Johnson and partner Protagonist secured FDA approval for Icotyde (icotrokinra), a once‑daily oral IL‑23 receptor antagonist for moderate‑to‑severe plaque psoriasis in adults and adolescents. Regulators reviewed the Iconic program of four phase III trials involving roughly 2,500 patients and cleared the drug based on consistent efficacy and a favorable safety profile, per company reports and trade coverage. Icotyde positions J&J to compete directly with high‑selling IL‑23 injectables such as Skyrizi and Tremfya by offering an oral dosing option. Market analysts and company guidance estimate peak sales in the multibillion‑dollar range, reflecting potential patient switching from injections and uptake among needle‑averse populations. The approval immediately reshapes commercial dynamics in immunodermatology and will prompt payers and prescribers to reassess treatment pathways. Manufacturers of biologic injectables will face new competitive pressures as an oral therapy narrows the efficacy gap with injectable IL‑23 blockade.